Iterum Therapeutics plc (ITRM)
| Market Cap | 48.70M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.55M |
| Shares Out | 27.52M |
| EPS (ttm) | -1.87 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 665,921 |
| Open | 1.750 |
| Previous Close | 1.750 |
| Day's Range | 1.750 - 1.810 |
| 52-Week Range | 0.808 - 3.020 |
| Beta | 2.31 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+182.49%) |
| Earnings Date | Nov 14, 2024 |
About ITRM
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland. [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ITRM stock is "Strong Buy" and the 12-month stock price forecast is $5.0.
News
Iterum Therapeutics Regains Full Nasdaq Compliance
Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market Iterum will Continue to be Listed and Traded on the Nasdaq Stock Market
Iterum Therapeutics plc (ITRM) Q3 2024 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2024 Earnings Conference Call November 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President, Legal Affairs Corey Fishman - Chief Ex...
Iterum Therapeutics Reports Third Quarter 2024 Financial Results
- - ORLYNVAH TM Approved by FDA on October 25, 2024— --Company to Host Conference Call Today at 8:30 a.m. EDT-- DUBLIN and CHICAGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: I...
Iterum Therapeutics plc (ITRM) U.S. FDA Approval of ORLYNVAH Call (Transcript)
Iterum Therapeutics plc (NASDAQ:ITRM) U.S. FDA Approval of ORLYNVAH October 28, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs & Secretary Corey Fishman - President, Directo...
Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Monday, October 28, 2024, at 8:30 a.m. EDT DUBLIN and CHICAGO , Oct. 28, 2024 /PRNewswire/ -- WHO: Iterum Therapeutics plc (Nasdaq: ITRM) is focused on deliveringdifferentiated anti-infectives aimed a...
Iterum Therapeutics Receives U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
ORLYNVAH ™ is the first oral penem approved for use in the U.S. and the second FDA-approved treatment for uUTIs in the past two decades
US FDA approves Iterum's treatment for urinary infection
The U.S. Food and Drug Administration has approved Iterum Therapeutics' oral antibiotic to treat a type of urinary tract infection (UTI) in adult women, the health regulator said on Friday.
Iterum Therapeutics to Present Data at IDWeek 2024
DUBLIN and CHICAGO, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV an...
Iterum Therapeutics to Participate at the 2024 Maxim Healthcare Virtual Summit
DUBLIN and CHICAGO, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral antibiotics to...
Iterum Therapeutics to Present at the 26th Annual H.C. Wainwright Global Investment Conference
DUBLIN, Ireland and CHICAGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next-generation oral anti...
Iterum Therapeutics plc (ITRM) Q2 2024 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q2 2024 Results Conference Call August 14, 2024 8:30 AM ET Company Participants Louise Barrett - Senior Vice President of Legal Affairs & Secretary Corey Fishman...
Iterum Therapeutics Reports Second Quarter 2024 Financial Results
- - FDA PDUFA Action Date of October 25, 2024; Advisory Committee Meeting on September 9, 2024— - -Cash Runway into 2025, including through PDUFA Action Date-- --Company to Host Conference Call Today ...
Iterum Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
DUBLIN and CHICAGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral and IV an...
Iterum Therapeutics Announces Expiration and Results of Rights Offering
DUBLIN and CHICAGO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV ...
Iterum Therapeutics Broadens Patent Estate for Oral Sulopenem
DUBLIN and CHICAGO, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibio...
Iterum Therapeutics Commences Rights Offering
DUBLIN and CHICAGO, July 22, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV ...
Iterum Therapeutics Announces FDA Advisory Committee Meeting to discuss NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
DUBLIN, Ireland and CHICAGO, June 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral ...
Iterum Therapeutics Receives FDA Acceptance of Resubmission of NDA for Oral Sulopenem for the treatment of Uncomplicated Urinary Tract Infections
Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024 Oral Sulopenem NDA has been assigned a PDUFA action date of October 25, 2024
Iterum Therapeutics plc (ITRM) Q1 2024 Earnings Call Transcript
Iterum Therapeutics plc (NASDAQ:ITRM) Q1 2024 Earnings Conference Call May 13, 2024 8:30 AM ET Company Participants Louise Barrett - SVP, Legal Affairs Corey N. Fishman - CEO Judith M.
Iterum Therapeutics Reports First Quarter 2024 Financial Results
- -NDA Resubmitted; FDA Action Expected in Early Q4 24-- - -Cash Runway into 2025, including through Potential FDA Approval--
Iterum Therapeutics to Report First Quarter 2024 Financial Results on May 13, 2024
DUBLIN, Ireland and CHICAGO, May 06, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral a...
Iterum Therapeutics Resubmits New Drug Application to U.S. Food and Drug Administration for Oral Sulopenem
--First Oral Penem in the U.S. and Second New Oral Treatment for uUTIs in Over 25 Years, if approved-- --Potential Approval Early Q4 2024--
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics plc (ITRM) Q4 2023 Earnings Call Transcript
Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
- -Resubmission of NDA On Track for Early Q2 24— - -Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Irela...
Iterum Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024
DUBLIN, Ireland and CHICAGO, March 21, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the Company), a clinical-stage pharmaceutical company focused on developing next generation oral...